DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
-1.67%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$5.11B
AUM Growth
+$5.11B
(-9.2%)
Cap. Flow
+$49.9M
Cap. Flow
% of AUM
0.98%
Top 10 Holdings %
Top 10 Hldgs %
36.57%
Holding
172
New
27
Increased
20
Reduced
18
Closed
38
Top Buys
| 1 |
Nuvalent
NUVL
|
$436M |
| 2 |
GeneDx Holdings
WGS
|
$105M |
| 3 |
Neurocrine Biosciences
NBIX
|
$40M |
| 4 |
Glaukos
GKOS
|
$29.8M |
| 5 |
AERI
Aerie Pharmaceuticals, Inc.
AERI
|
$24.5M |
Top Sells
| 1 |
Zimmer Biomet
ZBH
|
$54.4M |
| 2 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
$54.1M |
| 3 |
QuidelOrtho
QDEL
|
$52.4M |
| 4 |
Galapagos
GLPG
|
$45.3M |
| 5 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$42.5M |
Sector Composition
| 1 | Healthcare | 66.55% |
| 2 | Financials | 1.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CMRX
126
DELISTED
Chimerix, Inc.
CMRX
| – | – |
-1,816,221
| Closed | -$14.5M |
|
127
NeueHealth
NEUE
$60.6M
| – | – |
-1,400,000
| Closed | -$24M |
|
|
128
Zimmer Biomet
ZBH
$20.8B
| – | – |
-338,000
| Closed | -$54.4M |
|
129
Xeris Biopharma Holdings
XERS
$1.27B
| – | – |
-6,553,398
| Closed | -$26.7M |
|
130
Stereotaxis
STXS
$246M
| – | – |
-1,843,000
| Closed | -$17.8M |
|
131
Avidity Biosciences
RNA
$6.12B
| – | – |
-560,132
| Closed | -$13.8M |
|
|
132
QuidelOrtho
QDEL
$1.87B
| – | – |
-409,219
| Closed | -$52.4M |
|
133
Puma Biotechnology
PBYI
$258M
| – | – |
-3,769,795
| Closed | -$34.6M |
|
134
Owens & Minor
OMI
$423M
| – | – |
-996,500
| Closed | -$42.2M |
|
135
Lifestance Health
LFST
$2.14B
| – | – |
-400,000
| Closed | -$11.1M |
|
136
Janux Therapeutics
JANX
$1.38B
| – | – |
-700,000
| Closed | -$17.5M |
|
137
Insmed
INSM
$30.3B
| – | – |
-200,000
| Closed | -$5.69M |
|
138
Immunocore
IMCR
$1.78B
| – | – |
-360,966
| Closed | -$14.1M |
|
139
Monte Rosa Therapeutics
GLUE
$309M
| – | – |
-350,000
| Closed | -$7.95M |
|
|
140
Galapagos
GLPG
$2.06B
| – | – |
-657,005
| Closed | -$45.3M |
|
141
Amicus Therapeutics
FOLD
$2.42B
| – | – |
-2,941,492
| Closed | -$28.4M |
|
142
Dyne Therapeutics
DYN
$1.92B
| – | – |
-787,000
| Closed | -$16.6M |
|
143
Bioventus
BVS
$471M
| – | – |
-778,567
| Closed | -$13.7M |
|
144
Biomea Fusion
BMEA
$114M
| – | – |
-248,447
| Closed | -$3.88M |
|
|
BLUE
145
DELISTED
bluebird bio
BLUE
| – | – |
-480,300
| Closed | -$15.4M |
|
146
Aurinia Pharmaceuticals
AUPH
$1.58B
| – | – |
0
| – | – |
|
147
Ardelyx
ARDX
$1.57B
| – | – |
-3,811,554
| Closed | -$28.9M |
|
148
Agilon Health
AGL
$497M
| – | – |
-300,000
| Closed | -$12.2M |
|
149
Adverum Biotechnologies
ADVM
$68.2M
| – | – |
-2,827,000
| Closed | -$9.9M |
|